Sunshine Biopharma, Inc. is a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. The Company�s lead compound, Adva-27a is a multi-purpose anti-tumor. Its drug candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for various forms of cancer. As of December 31, 2011, the Company planned to conduct its Phase I clinical trials for Adva-27a. During the year ended December 31, 2011, the early stage preclinical studies for its lead compound, Adva-27a, were completed. As of December 31, 2011, the Company was focused on continuing its clinical development program of Adva-27a by conducting the next sequence of steps consist of the GMP Manufacturing (for use in IND-Enabling Studies and Phase I Clinical Trials); IND-Enabling Studies; Regulatory Filing (Fast-Track Status Anticipated), and Phase I Clinical Trials (Multidrug Resistant Breast Cancer Indication).